N+1 Singer Reiterates “Buy” Rating for Verona Pharma Plc (VRP)
Verona Pharma Plc (LON:VRP)‘s stock had its “buy” rating restated by N+1 Singer in a research note issued on Monday. They currently have a GBX 3.50 ($0.06) price target on the stock. N+1 Singer’s price target suggests a potential upside of 84.21% from the stock’s previous close.
Shares of Verona Pharma Plc (LON:VRP) traded down 32.53% on Monday, hitting GBX 1.40. 12,179,358 shares of the company’s stock traded hands. Verona Pharma Plc has a 1-year low of GBX 1.015 and a 1-year high of GBX 2.74. The stock’s 50-day moving average is GBX 2.12 and its 200-day moving average is GBX 2.96.
Verona Pharma plc is a biotechnology company. The Company is engaged in research, discovery and development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (LON:VRP), asthma, allergic rhinitis (hay fever), and cough.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.